DuPont de Nemours (NYSE:DD) Stock Gets Price Target Boost from Barclays

DuPont de Nemours (NYSE:DD) had its price objective raised by equities researchers at Barclays from $156.00 to $176.00 in a research note issued to investors on Wednesday, Benzinga reports. The firm presently has an “overweight” rating on the basic materials company’s stock. Barclays‘s target price indicates a potential upside of 13.52% from the company’s previous close.

Several other analysts also recently issued reports on DD. JPMorgan Chase & Co. downgraded DuPont de Nemours from an “overweight” rating to a “neutral” rating and decreased their price target for the stock from $172.00 to $145.00 in a research note on Friday, October 9th. Zacks Research downgraded DuPont de Nemours from a “strong-buy” rating to a “hold” rating in a report on Friday, July 17th. UBS Group dropped their price target on shares of DuPont de Nemours from $178.00 to $172.00 and set a “buy” rating on the stock in a research report on Monday, October 5th. Citigroup decreased their price objective on shares of DuPont de Nemours from $170.00 to $162.00 and set a “buy” rating for the company in a report on Wednesday, October 7th. Finally, Royal Bank Of Canada lowered their target price on shares of DuPont de Nemours from $176.00 to $160.00 and set an “outperform” rating on the stock in a research note on Thursday, October 15th. Twelve analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $163.25.

DuPont de Nemours Stock Up 1.0%

Shares of DD stock traded up $1.57 on Wednesday, hitting $155.03. The company’s stock had a trading volume of 870,396 shares, compared to its average volume of 1,342,499. The company has a debt-to-equity ratio of 0.23, a current ratio of 2.43 and a quick ratio of 1.82. DuPont de Nemours has a fifty-two week low of $111.15 and a fifty-two week high of $157.98. The firm’s fifty day moving average price is $132.64 and its 200-day moving average price is $138.51. The stock has a market capitalization of $20.94 billion, a price-to-earnings ratio of 345.12, a P/E/G ratio of 1.31 and a beta of 1.06.

DuPont de Nemours (NYSE:DD) last posted its earnings results on Tuesday, November 3rd. The basic materials company reported $2.09 EPS for the quarter, topping the consensus estimate of $1.87 by $0.22. DuPont de Nemours had a net margin of 0.67% and a return on equity of 6.92%. The firm had revenue of $1.87 billion for the quarter, compared to the consensus estimate of $1.84 billion. During the same period in the prior year, the business posted $1.09 earnings per share. The business’s quarterly revenue was up 4.1% on a year-over-year basis. Research analysts anticipate that DuPont de Nemours will post 7.25 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Physician Wealth Advisors Inc. increased its stake in DuPont de Nemours by 223.1% during the third quarter. Physician Wealth Advisors Inc. now owns 210 shares of the basic materials company’s stock valued at $27,000 after acquiring an additional 145 shares during the period. Elevation Wealth Partners LLC lifted its position in shares of DuPont de Nemours by 168.5% in the 2nd quarter. Elevation Wealth Partners LLC now owns 239 shares of the basic materials company’s stock worth $32,000 after acquiring an additional 150 shares during the period. DHJJ Financial Advisors Ltd. lifted its position in shares of DuPont de Nemours by 150.0% in the 3rd quarter. DHJJ Financial Advisors Ltd. now owns 250 shares of the basic materials company’s stock worth $32,000 after acquiring an additional 150 shares during the period. Bangor Savings Bank acquired a new stake in shares of DuPont de Nemours during the 3rd quarter worth approximately $36,000. Finally, Compass Wealth Management LLC acquired a new stake in shares of DuPont de Nemours during the 3rd quarter worth approximately $39,000. Institutional investors and hedge funds own 73.96% of the company’s stock.

DuPont de Nemours News Roundup

Here are the key news stories impacting DuPont de Nemours this week:

• Positive Sentiment: Earnings and sales beat expectations. Q3 adjusted EPS was $2.09 versus analysts’ $1.87 estimate, while revenue of about $1.9 billion topped expectations and grew 4% year over year. DuPont also reported 5% organic sales growth. DuPont Reports Third Quarter 2026 Results
• Positive Sentiment: 2026 guidance was raised again. DuPont said results exceeded its Q3 guidance and lifted its full-year forecast, citing strength in healthcare and aerospace demand. The outlook increase supports expectations for continued earnings growth. DuPont raises full-year profit forecasts
• Positive Sentiment: Shareholder returns and cash generation were robust. The company reported $341 million in transaction-adjusted free cash flow, completed substantial repurchases in Q3, and intends to buy back another $250 million of shares in Q4. DD Q3 Earnings Beat on Organic Growth, Raises 2026 Outlook
• Positive Sentiment: A new peptide-purification product may broaden DuPont’s life-sciences opportunity. The product announcement adds a potential growth avenue, though the available report provides no sales or financial contribution estimates. What Is DuPont Signaling With Its New Peptide Purification Product?

About DuPont de Nemours

DuPont de Nemours, Inc is a diversified science and technology company that develops engineered materials and specialty products for industrial and consumer markets. Its offerings are used in applications including electronics, semiconductor manufacturing, water purification, transportation, construction, healthcare, and worker and consumer protection.

The company’s product portfolio has historically included high-performance films, resins, adhesives, engineered polymers, specialty fibers, protective materials, water-treatment membranes, and filtration technologies.